Investigational Drug Information for LUM001
✉ Email this page to a colleague
What is the development status for investigational drug LUM001?
LUM001 is an investigational drug.
There have been 14 clinical trials for LUM001.
The most recent clinical trial was a Phase 2 trial, which was initiated on July 9th 2019.
The most common disease conditions in clinical trials are Cholestasis, Syndrome, and Liver Diseases. The leading clinical trial sponsors are Mirum Pharmaceuticals, Inc., Shire, and Lumena Pharmaceuticals, Inc.
There are ten US patents protecting this investigational drug and three hundred and seventy-eight international patents.
Summary for LUM001
| US Patents | 10 |
| International Patents | 378 |
| US Patent Applications | 39 |
| WIPO Patent Applications | 10 |
| Japanese Patent Applications | 9 |
| Clinical Trial Progress | Phase 2 (2019-07-09) |
| Vendors | 6 |
Recent Clinical Trials for LUM001
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS). | Mirum Pharmaceuticals, Inc. | Phase 2 |
| Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai | Mirum Pharmaceuticals, Inc. | Phase 2 |
| A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC) | Mirum Pharmaceuticals, Inc. | Phase 3 |
Clinical Trial Summary for LUM001
Top disease conditions for LUM001
Top clinical trial sponsors for LUM001
US Patents for LUM001
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| LUM001 | See Plans and Pricing | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions | SATIOGEN PHARMACEUTICALS, INC. (San Diego, CA) | See Plans and Pricing |
| LUM001 | See Plans and Pricing | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases | LUMENA PHARMACEUTIALS LLC (Lexington, MA) | See Plans and Pricing |
| LUM001 | See Plans and Pricing | Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake | G.D. Searle and Company (Skokie, IL) | See Plans and Pricing |
| LUM001 | See Plans and Pricing | Substituted 5-aryl-benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake | G.D. Searle and Company (Skokie, IL) | See Plans and Pricing |
| LUM001 | See Plans and Pricing | Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake | G.D. Searle and Company (Skokie, IL) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for LUM001
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| LUM001 | European Patent Office | EP2575821 | 2030-05-26 | See Plans and Pricing |
| LUM001 | European Patent Office | EP2995317 | 2030-05-26 | See Plans and Pricing |
| LUM001 | European Patent Office | EP3593802 | 2030-05-26 | See Plans and Pricing |
| LUM001 | Spain | ES2552657 | 2030-05-26 | See Plans and Pricing |
| LUM001 | World Intellectual Property Organization (WIPO) | WO2011150286 | 2030-05-26 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
